BioLight Life Sciences Ltd - Asset Resilience Ratio
BioLight Life Sciences Ltd (BOLT) has an Asset Resilience Ratio of 46.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how BioLight Life Sciences Ltd's Asset Resilience Ratio has changed over time. Check BioLight Life Sciences Ltd (BOLT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BioLight Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioLight Life Sciences Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA19.68 Million | 46.39% |
| Total Liquid Assets | ILA19.68 Million | 46.39% |
Asset Resilience Insights
- Very High Liquidity: BioLight Life Sciences Ltd maintains exceptional liquid asset reserves at 46.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioLight Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare BioLight Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
INVENTIVA ADS/1 O.N.
F:6IVA |
Biotechnology | 52.73% |
|
CorMedix Inc
NASDAQ:CRMD |
Biotechnology | 0.45% |
Annual Asset Resilience Ratio for BioLight Life Sciences Ltd (2005–2025)
The table below shows the annual Asset Resilience Ratio data for BioLight Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.39% | ILA19.68 Million ≈ $52.75K |
ILA42.41 Million ≈ $113.71K |
+35.40pp |
| 2024-12-31 | 10.99% | ILA3.75 Million ≈ $10.06K |
ILA34.12 Million ≈ $91.48K |
+10.25pp |
| 2023-12-31 | 0.75% | ILA250.00K ≈ $670.24 |
ILA33.45 Million ≈ $89.68K |
-6.68pp |
| 2022-12-31 | 7.42% | ILA4.23 Million ≈ $11.35K |
ILA57.01 Million ≈ $152.84K |
+7.04pp |
| 2021-12-31 | 0.38% | ILA245.00K ≈ $656.84 |
ILA64.17 Million ≈ $172.04K |
-30.41pp |
| 2020-12-31 | 30.79% | ILA19.96 Million ≈ $53.51K |
ILA64.83 Million ≈ $173.80K |
+24.65pp |
| 2019-12-31 | 6.14% | ILA4.60 Million ≈ $12.34K |
ILA74.95 Million ≈ $200.94K |
+5.71pp |
| 2018-12-31 | 0.43% | ILA387.00K ≈ $1.04K |
ILA90.28 Million ≈ $242.04K |
-1.24pp |
| 2017-12-31 | 1.66% | ILA412.00K ≈ $1.10K |
ILA24.76 Million ≈ $66.39K |
+0.48pp |
| 2016-12-31 | 1.18% | ILA417.00K ≈ $1.12K |
ILA35.31 Million ≈ $94.67K |
+0.57pp |
| 2015-12-31 | 0.61% | ILA385.00K ≈ $1.03K |
ILA63.27 Million ≈ $169.63K |
-15.24pp |
| 2014-12-31 | 15.85% | ILA6.41 Million ≈ $17.18K |
ILA40.43 Million ≈ $108.40K |
+15.31pp |
| 2013-12-31 | 0.54% | ILA185.00K ≈ $495.98 |
ILA34.33 Million ≈ $92.04K |
-0.92pp |
| 2012-12-31 | 1.46% | ILA610.00K ≈ $1.64K |
ILA41.89 Million ≈ $112.31K |
-22.26pp |
| 2011-12-31 | 23.72% | ILA7.03 Million ≈ $18.84K |
ILA29.63 Million ≈ $79.44K |
+2.44pp |
| 2010-12-31 | 21.28% | ILA2.16 Million ≈ $5.79K |
ILA10.14 Million ≈ $27.18K |
-27.61pp |
| 2009-12-31 | 48.90% | ILA11.00 Million ≈ $29.48K |
ILA22.49 Million ≈ $60.29K |
-31.56pp |
| 2006-12-31 | 80.46% | ILA38.75 Million ≈ $103.89K |
ILA48.16 Million ≈ $129.12K |
-4.55pp |
| 2005-12-31 | 85.01% | ILA17.33 Million ≈ $46.47K |
ILA20.39 Million ≈ $54.66K |
-- |
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more